MCM
TRIB

Marathon Capital Management’s Trinity Biotech TRIB Stock Holding History

Marathon Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-4,450
Closed -$153K – 87
2016
Q4 		$153K Sell
4,450
-19,870
-82% -$684K 0.07% 73
2016
Q3 		$1.61M Buy
24,320
+2,645
+12% +$165K 0.8% 25
2016
Q2 		$1.23M Sell
21,675
-1,150
-5% -$64.8K 0.63% 27
2016
Q1 		$1.33M Buy
22,825
+4,610
+25% +$245K 0.69% 25
2015
Q4 		$1.07M Buy
+18,215
New +$1.08M 0.57% 31

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return

Marathon Capital Management's TRIB Position: Q1 2017 in Review

Marathon Capital Management sold out of Trinity Biotech (TRIB) in Q1 2017, closing a stake of 4,450 shares — an estimated $153K sold.

Marathon Capital Management first reported a position in TRIB in Q4 2015 and held it in 5 quarters. The position peaked at $1.61M in Q3 2016. 67 funds tracked by Wall St. Rank hold TRIB as of Q1 2017.

  • Marathon Capital Management reported no remaining Trinity Biotech position as of Q1 2017 after selling out during the quarter.
  • Marathon Capital Management sold 4,450 Trinity Biotech shares in Q1 2017, an estimated $153K.
  • Marathon Capital Management first reported a position in Trinity Biotech in Q4 2015 and held it in 5 quarters.
  • Marathon Capital Management's Trinity Biotech position peaked at $1.61M in Q3 2016.
  • 67 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2017.

Based on Marathon Capital Management's 13F filing for Q1 2017, filed 4 May 2017.